Company / SG&A per Share
Denali Therapeutics Inc. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.95
FY2025
5-year range
$0.39 / $0.95
FY2021-FY2025
Trend
+24.3%
vs FY2024
Sector context
#129 of 210
Health Care
What the data says
At $0.95, Denali Therapeutics Inc.'s sg&a per share ranks #82 of 210 in the Health Care sector. SG&A per Share has increased for 7 consecutive years, from $0.13 in FY2018 to $0.95 in FY2025.
Based on SEC 10-K filings.
0.95 in FY2025 with a 5-year CAGR of +23.0%.
Increased from $0.76 to $0.95 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +24.3%
- 5-Year CAGR
- +23.0%
- 10-Year CAGR
- -
Sector benchmark
#82 of 210 in Health CareTop 39% of 210This company $0.95 Sector average $29.50
▼
-96.8% below sector average
Key checks
Key Insights
- Denali Therapeutics Inc.'s sg&a per share has grown for 7 consecutive years.
- In FY2025, sg&a per share increased 24.3% year-over-year.
- Ranks #129 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.95 | +24.3% |
| FY2024 | $0.76 | +0.2% |
| FY2023 | $0.76 | +54.1% |
| FY2022 | $0.49 | +27.9% |
| FY2021 | $0.39 | +14.7% |
| FY2020 | $0.34 | +103.0% |
| FY2019 | $0.17 | +23.5% |
| FY2018 | $0.13 | -87.2% |
| FY2017 | $1.05 | -42.6% |
| FY2016 | $1.83 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026